Assessment of posaconazole salvage therapy in chronic pulmonary aspergillosis using predefined response criteria

Chronic pulmonary aspergillosis (CPA) is a slowly progressive infection mainly caused by Aspergillus fumigatus, characterized by inflammatory destruction of lung tissue with cavitation, pleural thickening and/or fibrosis, and associated with significant respiratory and constitutional symptoms [1 –3]. CPA usually affects patients with underlying structural airway disease with air-filled cavities or bullae, such as tuberculosis (TB), non-tuberculous mycobacterial infection, chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), pneumothorax and sarcoid osis.
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Source Type: research